Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Rozerem Recommended for Approval
February 8, 2010
- DSP to Transfer Growth Hormone Business to JCR
February 8, 2010
- PMDA Needs Internal Renovation: Prof. Kami
February 8, 2010
- Pregabalin to Drive Pfizer's Primary Case Business: Mr Harada
February 8, 2010
- Panel on Unapproved Drugs to Hold 1st Meeting
February 8, 2010
- Kyowa Kirin Aims at Pharm. Sales of \225.0 Bil. in FY2012
February 8, 2010
- Medical Fees Up for the 1st Time in 10 Years, But Drug Prices Down 6.5%
February 8, 2010
- Zeria to Overcome NHI Price Cuts through Synergism with Tillotts: President Ibe
February 8, 2010
- Present Scientific Grounds for Combination Drugs
February 8, 2010
- GLP-1 Analogues to Be Recommended for Severe DM
February 1, 2010
- Teva-Kowa Acquires 2/3 of Taisho Pharm's Shares
February 1, 2010
- NIHS's Working Group Finds No Problems with Generics of 9 APIs
February 1, 2010
- Sciele Pharma Renamed Shionogi Pharma
February 1, 2010
- EPO's Biosimilar Approved: JCR, Kissei
February 1, 2010
- Kyowa Kirin Revises Business Forecasts Downward
February 1, 2010
- JGA President Expresses Hope for the New Pricing System
February 1, 2010
- Iwaki Posts Net Losses Two Years in a Row
February 1, 2010
- High Out-of-Pocket Expenses Cited by 38.4% of Households Not Seeing Doctor
February 1, 2010
- 29 Products Approved Including Japan's 1st GLP-1 Analogue
February 1, 2010
- Ethical Drugs Show Double-Digit Growth for the First Time in FY2009: Crecon
February 1, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…